Similar to shared neoantigens such as mutant KRAS, personalized neoantigens are selectively expressed on tumor cells and have strong affinity for MHC, thus evading central tolerance and mitigating the toxicity caused by the lack of specificity of TAAs [76]. Here, KRAS is linked to neoplasm.